Breakout Stocks
TNGX is part of our breakout stocks list, indicating it is showing strong recent technical strength.
TANGO THERAPEUTICS INC (TNGX) Stock Price & Overview
NASDAQ:TNGX • US87583X1090
Current stock price
21.56 USD
+1.61 (+8.07%)
At close:
21.56 USD
0 (0%)
After Hours:
The current stock price of TNGX is 21.56 USD. Today TNGX is up by 8.07%. In the past month the price increased by 24.62%. In the past year, price increased by 1571.32%.
TNGX Key Statistics
52-Week Range1.03 - 22.2
Current TNGX stock price positioned within its 52-week range.
1-Month Range17.25 - 22.2
Current TNGX stock price positioned within its 1-month range.
- Market Cap
- 3.076B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.86
- Dividend Yield
- N/A
TNGX Stock Performance
Today
+8.07%
1 Week
+6.26%
1 Month
+24.62%
3 Months
+65.72%
Longer-term
6 Months +138.76%
1 Year +1,571.32%
2 Years +180.00%
3 Years +534.12%
5 Years N/A
10 Years N/A
TNGX Stock Chart
TNGX Stock Screens
TNGX currently appears in the following ChartMill screener lists.
Breakout Setups
TNGX appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
Most Shorted Stocks
TNGX is part of our most shorted stocks screen list, indicating it has a high short interest.
TNGX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TNGX. When comparing the yearly performance of all stocks, TNGX is one of the better performing stocks in the market, outperforming 99.75% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
TNGX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TNGX. TNGX has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TNGX Earnings
Next Earnings DateMay 11, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported-$0.29
Revenue Reported
EPS Surprise 11.15%
Revenue Surprise -100.00%
TNGX Forecast & Estimates
17 analysts have analysed TNGX and the average price target is 21.83 USD. This implies a price increase of 1.24% is expected in the next year compared to the current price of 21.56.
For the next year, analysts expect an EPS growth of -58.04% and a revenue growth -100% for TNGX
Analysts
Analysts85.88
Price Target21.83 (1.25%)
EPS Next Y-58.04%
Revenue Next Year-100%
TNGX Groups
Sector & Classification
TNGX Financial Highlights
Over the last trailing twelve months TNGX reported a non-GAAP Earnings per Share(EPS) of -0.86. The EPS increased by 28.93% compared to the year before.
Income Statements
Revenue(TTM)62.38M
Net Income(TTM)-101.59M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.48% | ||
| ROE | -29.35% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%17.14%
Sales Q2Q%-100%
EPS 1Y (TTM)28.93%
Revenue 1Y (TTM)48.29%
TNGX Ownership
Ownership
Inst Owners120.49%
Shares142.69M
Float140.01M
Ins Owners1.44%
Short Float %33.74%
Short Ratio13.89
TNGX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 367.796B | ||
| AMGN | AMGEN INC | 15.32 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.94 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.34 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TNGX
Company Profile
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Boston, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2020-09-03. The firm's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The company is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. The company is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
Company Info
IPO: 2020-09-03
TANGO THERAPEUTICS INC
201 Brookline Avenue, Suite 901
Boston MASSACHUSETTS US
CEO: Aaron I. Davis
Employees: 137
Phone: 18573204900
TANGO THERAPEUTICS INC / TNGX FAQ
What does TANGO THERAPEUTICS INC do?
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Boston, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2020-09-03. The firm's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The company is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. The company is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
What is the stock price of TANGO THERAPEUTICS INC today?
The current stock price of TNGX is 21.56 USD. The price increased by 8.07% in the last trading session.
Does TANGO THERAPEUTICS INC pay dividends?
TNGX does not pay a dividend.
What is the ChartMill technical and fundamental rating of TNGX stock?
TNGX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Would investing in TANGO THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TNGX.
What is the employee count for TNGX stock?
TANGO THERAPEUTICS INC (TNGX) currently has 137 employees.
Who owns TANGO THERAPEUTICS INC?
You can find the ownership structure of TANGO THERAPEUTICS INC (TNGX) on the Ownership tab.